Auranofin
- Generic Name
- Auranofin
- Brand Names
- Ridaura
- Drug Type
- Small Molecule
- Chemical Formula
- C20H34AuO9PS
- CAS Number
- 34031-32-8
- Unique Ingredient Identifier
- 3H04W2810V
- Background
Auranofin is a gold salt that is capable of eliciting pharmacologic actions that suppress inflammation and stimulate cell-mediated immunity. It has subsequently been listed by the World Health Organization as a member of the antirheumatic agent category. Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA. Heme oxygenase 1 is an inducible heme-degrading...
- Indication
Used in the treatment of active, progressive or destructive forms of inflammatory arthritis, such as adult rheumatoid arthritis.
- Associated Conditions
- Rheumatoid Arthritis
- Associated Therapies
- -
Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-08-18
- Last Posted Date
- 2016-01-18
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT01419691
- Locations
- 🇺🇸
University of Kansas Cancer Center, Westwood, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath